The majority of human skeletal dysplasias are caused by dysregulation of growth plate homeostasis. As TGF-β signaling is a critical determinant of growth plate homeostasis, skeletal dysplasias are often associated with dysregulation of this pathway. The context-dependent action of TFG-β signaling is tightly controlled by numerous mechanisms at the extracellular level and downstream of ligand-receptor interactions. However, TGF-β is synthesized as an inactive precursor that is cleaved to become mature in the Golgi apparatus, and the regulation of this posttranslational intracellular processing and trafficking is much less defined. Here, we report that a cysteine-rich protein, E-selectin ligand-1 (ESL-1), acts as a negative regulator of TGF-β production by binding TGF-β precursors in the Golgi apparatus in a cell-autonomous fashion, inhibiting their maturation. Furthermore, ESL-1 inhibited the processing of proTGF-β by a furin-like protease, leading to reduced secretion of mature TGF-β by primary mouse chondrocytes and HEK293 cells. In vivo loss of Esl1 in mice led to increased TGF-β/SMAD signaling in the growth plate that was associated with reduced chondrocyte proliferation and delayed terminal differentiation. Gain-of-function and rescue studies of the Xenopus ESL-1 ortholog in the context of early embryogenesis showed that this regulation of TGF-β/Nodal signaling was evolutionarily conserved. This study identifies what we believe to be a novel intracellular mechanism for regulating TGF-β during skeletal development and homeostasis.
Introduction
The body size of mammalian vertebrates is specified by endochondral ossification. Therefore, it is not surprising that a majority of human skeletal dysplasias are caused by dysregulation of growth plate homeostasis. The growth plate is composed of differentiating chondrocytes that occupy histologically distinct zones: (a) the resting zone (RZ) is the reservoir of chondrocyte progenitors; (b) the proliferating zone (PZ) contains actively proliferating chondrocytes important in bone elongation; (c) the hypertrophic zone (HZ) contains ECM-rich terminally differentiated chondrocytes. Chondrocyte differentiation and homeostasis are precisely regulated by interaction of signaling pathways including bone morphogenetic protein (BMP), TGF-β, Wnt, Hedgehog, and parathyroid hormone-related protein (PTHrP). These signaling molecules act directly or indirectly on chondrocytes within the growth plate as well as on cells of the perichondrium and periosteum. Dysregulation of these signaling pathways is a major cause of defective growth plate homeostasis and skeletal dysplasias (1, 2) .
In vertebrates, a major source of TGF-β production is the skelcysteine-rich FGF receptor 1 (CFR-1) and latent TGF-β complex protein 1 (LTCP-1). However, the function of ESL-1 has largely remained unknown. Here, we studied an Esl1-knockout mouse that unexpectedly exhibited a skeletal dysplasia phenotype. We discovered that ESL-1 plays an important role by inhibiting TGF-β maturation/bioavailability via an intracellular mechanism that is distinct from previously characterized ones that act within the ECM environment or downstream of ligand-receptor interaction.
Results

Loss of ESL-1 causes skeletal dysplasia. Because ESL-1 was identified
as an E-selectin-interacting protein, its role in the regulation of leukocyte rolling was predicted (6) . To test this, we generated Esl1 -/-mice (Supplemental Figure 1 ; supplemental material available online with this article; doi:10.1172/JCI42150DS1) but did not find obvious defects in leukocyte rolling and blood count (data not shown and personal communication, K. Ley, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA). Instead, loss of ESL-1 causes distinctive skeletal and growth defects. At birth, heterozygous mice were phenotypically normal, while Esl1 -/-mice were approximately 30%-50% smaller than their WT littermates ( Figure 1A ). This was noted from E14.5 through maturity (Supplemental Figure 2 ). Skeletal preparations of Esl1 -/-mice showed generalized shortening and thinning of all bony elements and distinctively narrow rib cages ( Figure 1A ). P1 Esl1 -/-mice showed shortening of the growth plates that affected both the PZ and HZ, with decreased chondrocyte cell density and increased ECM deposition ( Figure 1 , B and C). The shortening of the growth plate was due in part to decreased chondrocyte proliferation, as quantified by BrdU incorporation assay ( Figure 1D ). These results suggest an important role of ESL-1 in skeletogenesis.
In human cells, an ESL1 splicing variant termed GLG2 was identified that encodes a protein with 24 additional amino acids in the C terminal of ESL-1 (8) . However, the GLG2 isoform was found specifically in the primates but not in any non-primate species including mice, suggesting that ESL-1 but not GLG2 plays a major role in the molecularly conserved processes governing of skeletogenesis.
In addition to being widely expressed in various tissues including brain, kidney, intestine, etc., Esl1 is highly expressed in the skeletal system, including intervertebral discs at E12.5 (Supplemental Figure 3 ) and perichondrium and periosteum from E16.5 to P1, and shows increased expression in growth plate chondrocytes at P1 time points (Figure 1 , E-G). Interestingly, the Esl1 expression pattern correlates well with TGF-βs expression patterns in all tested tissues in mouse embryos (9 activity. However, we detected similar levels of phosphorylated MEK1/2 (p-MEK1/2), the major downstream effectors of FGF signaling during chondrogenesis (13) , in P3 rib cartilage of Esl1 -/-mice versus WT littermates (Figure 2A ). Furthermore, we tested potential FGF/ESL-1 in vivo interaction by generating Esl1 -/-Fgfr3 -/-mice. If loss of ESL-1 were to upregulate FGF activity in the skeleton, then loss of FGFR3 should compensate for this effect and rescue the Esl1 -/-growth retardation. Instead, we found that the Esl1 -/-Fgfr3 -/-mice were similar to Esl1 -/-littermates in size. Additionally, 4-week-old Esl1 -/-and Esl1 -/-Fgfr3 -/-mice showed similar shortening of PZ and HZ in their growth plates ( Figure 2 , B and C, and Supplemental Figure 4) . Hence, the Esl1 -/-phenotype is dominant over the loss of Fgfr3 -/-without evidence of epistasis, suggesting that FGF/FGFR3 signaling is not the major target of ESL-1 in cartilage.
ESL-1 upregulates TGF-β signaling in the growth plate. Because ESL-1 and TGF-β1 were found to copurify from a CHO cell line stably expressing TGF-β1 (7), we evaluated whether TGF-β signaling was perturbed in Esl1 -/-growth plates. By immunofluorescence, we detected significantly increased numbers of phosphorylatedSmad2-positive (p-Smad2-positive) cells in the P1 Esl1 -/-growth plate with α-tubulin or total Smad2 as a control ( Figure 3A and Supplemental Figure 5 ). Western blot analysis confirmed that in P3 Esl1 -/-rib cartilage protein, p-Smad2 was increased approximately 2-fold compared with that in WT mice, but the levels of phosphorylated Smad-1 and -5 were similar ( Figure 3B ), suggesting that TGF-β rather than BMP signaling was upregulated. Additionally, using a stable mink lung TGF-β reporter cell line (14) , we found that conditioned medium from primary Esl1 -/-chondrocyte culture exhibited higher TGF-β activity than that from WT chondrocytes ( Figure 3C ). Furthermore, in Esl1 -/-mouse embryonic fibroblasts (MEFs), TGF-β downstream targets P21 (CDK inhibitor 1A), connective tissue growth factor (Ctgf), and plasminogen activator inhibitor 1 (PAI-1) were all upregulated, but Tgfb1 and Tgfb2 mRNA levels were unchanged ( Figure 3D ). These data suggest that loss of ESL-1 increased TGF-β signaling but not TGF-β expression and that the elevated TGF-β signaling may inhibit chondrocyte proliferation in the Esl1 -/-growth plate.
We next evaluated the expression of chondrocyte markers by quantitative RT-PCR (qRT-PCR) of P3 rib cartilage RNA. Chondrocyte terminal differentiation markers, i.e., Col10a1 for hypertrophic chondrocytes and Indian hedgehog (Ihh) for prehypertrophic chondrocytes, were downregulated in Esl1 -/-cartilage, while the markers for proliferating or resting chondrocytes, i.e., Sox9, Col2a1, and Pthrp, were increased in the mutant samples ( Figure 3E ). Furthermore, in situ hybridization showed that the Ihh-positive zone (preHZ) in Esl1 -/-growth plate was narrower, with weaker signal intensity than in the WT sample ( Figure 3F ). During cartilage homeostasis, IHH and PTHrP cooperatively specify the transition of chondrocytes from proliferation to differentiation (15) . IHH upregulates PTHrP through TGF-β, while PTHrP negatively regulates IHH expression (16) . Moreover, loss of Ihh in mice leads to severely delayed proliferation and differentiation in growth plate chondrocytes. Therefore, the qRT-PCR data explain the Esl1 -/-growth plate phenotype: the loss of ESL-1 augmented TGF-β signaling, which subsequently increased PTHrP expression and, accordingly, suppressed IHH expression in the negative feedback loop. This led to delayed chondrocyte proliferation and differentiation by shifting the IHH/PTHrP balance toward PTHrP. However, it is worth mentioning that PTHrP is commonly considered as a factor that maintains chondrocytes in an undifferentiated but proliferating mode. Hence, the decreased proliferation observed in Esl1 -/-chondrocytes may be a result of other TGF-β downstream mechanisms outside the PTHrP/IHH axis. We also found that Sox9 and its direct downstream target Col2a1 are both increased in the mutant rib cartilage, consistent with previous observations that Hedgehog signaling is a negative regulator of Sox9 expression in the growth plate (17) . 
Gain of ESL-1 function in cartilage yields an growth plate phenotype opposite that resulting from loss of ESL-1 function.
Since TGF-β can signal in both a paracrine and endocrine fashion, we overexpressed the Esl1 transgene using the Col2a1 cartilage-specific promoter in mice to determine whether ESL-1 acts directly on the cartilage via regulation of locally synthesized TGF-β. The Col2a1-Esl1 transgenic mice displayed increased proliferative chondrocytes, decreased ECM disposition, higher cell density in both the PZ and preHZ, and a longer preHZ ( Figure 4 , A-C). By Western blot analysis, decreased p-Smad2 was detected in the transgenic P3 rib cartilage, indicating downregulated TGF-β activity ( Figure 4D ). By qRT-PCR of transgenic rib cartilage ( Figure 4E ), we detected decreased Col2a1, Sox9, and Pthrp but increased Col10a1 and Ihh. These results are in contrast to the qRT-PCR data from the Esl1 -/-cartilage. Additionally, increased Ihh expression in the preHZ was confirmed by in situ hybridization in P3 transgenic tibias ( Figure 4F ). Together, these data show that, as predicted, gain of ESL-1 expression within chondrocytes was sufficient to perturb a growth plate phenotype opposite to that caused by the generalized ESL-1 loss of function. Interestingly, the phenotype of Esl1 transgenic growth plate is reminiscent of that described in Ltbp3 -/-mice. Latent TGF-β-binding protein 3 (LTBP3) regulates TGF-β secretion and bioavailability in bone and cartilage homeostasis. Loss of LTBP3 decreased TGF-β signaling and led to accelerated chondrocyte differentiation and hypertrophy (18) . P3 Ltbp3 -/-mutant mouse growth plates showed a longer hypertrophic chondrocyte zone and higher cell density in the PZ (Supplemental Figure 6A) . p-Smad2-positive cells were also greatly decreased in the Ltbp3 -/-growth plate chondrocytes (Supplemental Figure 6B ). Together these data show that the decrease in TGF-β signaling observed in the 2 distinct genetic models of Col2a1-Esl1 transgenic and Ltbp3 -/-mice caused similar growth plate phenotypes.
ESL-1 antagonizes TGF-β signaling in Xenopus laevis.
To further evaluate the antagonistic role of ESL-1 in the TGF-β signaling pathway, we performed several experiments using Xenopus laevis as a model system. Xenopus utilizes most of the signaling pathways found in mammals, and changes in these pathways lead to dramatic and distinctive embryonic phenotypes. For this reason, Xenopus embryos have been used extensively as a robust and sensitive system to explore functions of individual components of several signaling pathways. Although the role of TGF-β1-3 in Xenopus is not well defined, other TGF-β family members that share the same precursor-cleavage mechanism and downstream Smad transducers have been well studied in Xenopus. For example, it was shown that Xenopus nodal related 1-4 (Xnr1-4), members of the nodal subclass of TGF-β proteins, play major roles in Xenopus body axis formation utilizing well-defined TGF-β signaling pathways. We reasoned that if ESL-1 acts as an antagonist of Xnrs, overexpression of ESL-1 would lead to a phenotype similar to that of deficiency of one or more Xnr members (19, 20) .
To this end, Xenopus Esl1 (xEsl1) mRNA was injected into the dorsal marginal zone of Xenopus embryos at the 2-cell stage (Supplemental Figure 7) . We found that injected embryos at stage 37 exhibited a highly reproducible phenotype, characterized by severe trunk curvature and shortened axis ( Figure 5A ). At stage 17, the neural folds of injected embryos formed around the yolk plug but did not join together (Supplemental Figure 8) . In contrast, when equal amounts of xEsl1 mRNA were injected into the ventral marginal zone, embryos developed normally and displayed no obvious abnormalities at gastrula, neurula, and tail bud stages, suggesting a highly specific dorsal function of ESL-1 ( Figure 5A and Supplemental Figure 8) . Furthermore, the phenotype of xEsl1 dorsal injection was dosage dependent (Supplemental Table 1 ). In addition, when mouse Esl1 mRNA was injected into Xenopus embryos, we observed phenotypes that were similar to, albeit less severe than, those with xEsl1 injections (data not shown). The phenotype of xEsl1-injected embryos strongly resembled that caused by deficiency of Xnr3, a TGF-β/Nodal member that specifies convergent extension movements. However, the xEsl1-injected embryos are distinct from Xnr1-, Xnr2-, or Xnr4-deficient embryos, whose phenotypes are considerably weaker than that resulting from Xnr3 deficiency (19) . Thus, we decided to focus on the relationship between xEsl1 and Xnr3 in our studies. During body axis formation, Xnr3 expression is restricted to the organizer region, and it is essential for the expression of mesoderm markers such as Xbra and MyoD (19, 20) . By in situ hybridization, the dorsal segment of the ring and the notochord showed reduced or absent expression of Xbra and MyoD in xEsl1-injected embryos ( Figure 5B ), indicating that the Xnr3 signal was markedly impaired by overexpression of xEsl1.
Rescue experiments were performed to explore the specific effect of ESL-1 on TGF-β regulation. We coinjected mRNAs of xEsl1 (300 pg) and Xnr3 (full-length pro-protein with LAP domain) (13 pg) into the dorsal marginal zone of 2-cell-stage embryos. Embryos were scored for abnormalities such as curved trunk and shortened axis. We found that coexpression of Xnr3 partially rescued the xEsl1-induced phenotype by approximately 50% on average in all independent tests ( Figure 5C and Supplemental Table 2 ). The lack of full rescue may be partly explained by participation of additional TGF-β proteins in dorsal axis formation (19) . In summary, the overexpression and rescue experiments showed that ESL-1 antagonism of TGF-β signaling is specific and evolutionarily conserved.
ESL-1 interacts with TGF-βs intracellularly and inhibits TGF-β/Smad signaling in a cell-autonomous fashion. ESL-1 (LTCP-1) was copurified with proTGF-β1 in a large protein complex in the medium of CHO cells stably expressing TGF-β1 (7). In addition, although the majority of published data indicated that ESL-1 is localized in the Golgi apparatus, its alternatively glycosylated variant identified in epithelial cancer tissues was either on the cell surface or secreted (21) , suggesting that the different subcellular localization of ESL-1 may be cell type specific. Therefore, possible mechanisms for ESL-1 inhibition of TGF-β may include: (a) intracellular inhibition of TGF-β bioavalibility, in a cell-autonomous fashion, or (b) extracellular interference with the interaction between secreted TGF-β and TGF-β receptors. To differentiate between these two possibilities, we first detected ESL-1 subcellular localization by immunostaining. We found that ESL-1 was restrictedly localized in the Golgi apparatus of most mouse tissues, e.g., in cartilage, and also in cell lines such as COS7 cells and MEFs, but it was detected at low levels in the ECM (see below). Second, by nonreducing Western blot assay on lysates from HEK293, HeLa, and COS7 cells cotransfected with proTGF-β1 and ESL-1, we found that ESL-1 was neither secreted with TGF-β nor bound to TGF-β covalently (Supplemental Figure 9) . These data suggest that in these tested tissues and cell lines, ESL-1 is most likely to act intracellularly to regulate TGF-β bioavalibility. Hence, we next studied whether the intracellular ESL-1 can bind to TGF-β in a noncovalent manner. We coexpressed Myc-tagged ESL-1 and V5-tagged TGF-β1 or TGF-β2 in COS7 cells and performed coimmunoprecipitation assays. The anti-Myc antibody precipitates contained both the full-length proTGF-βs (~50 kDa) and mature TGF-β peptides (15 kDa for TGF-β1 and 12 kDa for TGF-β2), while anti-V5 antibody (TGF-β) precipitated ESL-1 as well ( Figure 6A ). However, when we incubated recombinant human TGF-β1 (rhTGF-β1, the mature TGF-β1 ligand) with the lysate of ESL-1-Myc-transfected cells, the rhTGF-β1 could not be coprecipitated with ESL-1 ( Figure 6B ). These data suggest that ESL-1 binds to TGF-β noncovalently within the cell and that LAP is required for this interaction.
Because of the intracellular binding between TGF-β and ESL-1, we hypothesized that ESL-1 should regulate TGF-β in a cellautonomous fashion. To test this, we expressed TGF-β1 and/or ESL-1 in COS7 cells, and tested the conditioned medium with the mink lung TGF-β reporter cells. In our study, ESL-1 could not alter the reporter activity induced by exogenous addition of rhTGF-β1. However, reporter activity was reduced by ESL-1 when proTGF-β1 was expressed endogenously from transfected plasmids ( Figure 6C ). These data suggest that ESL-1 inhibits TGF-β in a cell-autonomous fashion, instead of acting as a cell surface or matrix decoy receptor for TGF-βs.
ESL-1 blocks TGF-β maturation by furin proteases.
The Golgi apparatus is an important site for TGF-β maturation and secretion, i.e., the cleavage of TGF-β by furin proteases and the cosecretion of TGF-β with LTBPs (4, 22) . The Golgi localization of ESL-1 and its functional inhibition of TGF-β signaling suggested that it may act at the level of TGF-β maturation. In fact, we found that TGF-β2, a predominant TGF-β family member in growth plate, was processed to a greater extent in Esl1 -/-rib cartilage and also cultured Esl1 -/-primary chondrocytes compared with WT counterparts ( Figure 7A and Supplemental Figure 10 ). In contrast, activin βA, another TGF-β family member that is also expressed in growth plate and upstream of Smad2/3 signaling, was not processed differently between mutant and WT cartilage samples (Supplemental Figure 11 ). These data suggest that ESL-1's effects on p-Smad2 activity in the growth plate homeostasis occur primarily via inhibition of TGF-β2 maturation.
Furthermore, this finding was confirmed by a gain-of-function experiment in cell culture. COS7 cells were transfected with either proTGF-β1-V5 or proTGF-β1-V5/ESL-1-Myc. Cycloheximide or bafilomycin was added to minimize possible interference from overexpression of proteins and lysosomal processing. In the presence of ESL-1, decreased amounts of mature TGF-β peptide and LAP were detected in cell lysates. At the same time, increased amounts of the proTGF-β1 dimer (~100 kDa under nonreducing conditions) were detected in the lysate of ESL-1/ TGF-β1 cotransfected cells. Less mature TGF-β1 was also detected in the culture medium of the cotransfected cells ( Figure 7B ). Similar trends were noted in cycloheximide-and/or bafilomycin-treated cells.
To test whether ESL-1 can specifically inhibit TGF-β maturation catalyzed by exogenously added furin protease, we incubated furin in a kinetic study with cell lysates from HEK293 cells transfected with either proTGF-β1-V5 or proTGF-β1-V5/ESL-1-Myc ( Figure 7C ). As expected, increasing ratios of ligand to proTGF-β1 were observed in both transfection schemes, with prolonged incubation showing furin-mediated cleavage of proTGF-β1 to mature TGF-β1. At shorter incubation time points (0-30 minutes), TGF-β1 processing by furin was similar irrespective of the presence of ESL-1. However, at later time points (1-3 hours) , the presence of ESL-1 stabilized proTGF-β1 and inhibited the production of TGF-β1 mature peptide ( Figure 7C ). To confirm the mechanism using a loss-of-function approach and to determine whether it was also present in chondrocytes, we performed another furin assay using lysates from the primary chondrocytes derived from P3 Esl1 -/-and WT rib cartilage. We found that in the absence of ESL-1, TGF-β2 maturation was accelerated, with increased accumulation of the mature peptide with duration of incubation ( Supplemental Figure 12) . These data support that ESL-1 binding to TGF-β inhibits furin-mediated TGF-β maturation. (C) ESL-1 can effectively inhibit TGF-β activity from the plasmid-produced proTGF-β1 but cannot inhibit signaling from the exogenously added rhTGF-β1 (n = 3; **P < 0.01).
To determine whether the alteration of intracellular TGF-β maturation would ultimately lead to a change of extracellular mature TGF-β, we performed a pulse-chase experiment. In the presence of ESL-1, decreased amounts of cleaved TGF-β1 were secreted into the medium, while increased amounts of proTGF-β were retained in cells at all time points tested (Supplemental Figure 13) . These results support the contention that ESL-1 inhibits the maturation/processing of proTGF-β intracellularly, ultimately leading to decreased extracellular amounts of active TGF-β ligand.
ESL-1 increases TGF-β localization in the Golgi apparatus.
We evaluated ESL-1 and TGF-β subcellular localization by expressing proTGF-β1-V5 and Myc-tagged ESL-1 in COS7 cells. ESL-1 was primarily localized in the Golgi apparatus in transfected cells (Figure 8, E-G) . In the absence of ESL-1 expression, TGF-β1 was abundantly distributed throughout the cytoplasm, including in the ER
Figure 7
ESL-1 inhibits TGF-β proteolytic processing. (A) ESL-1 inhibits the intracellular cleavage and maturation of proTGF-β2 in vivo as shown by the relative abundance of mature TGF-β2 and proTGF-β2 on Western blot analysis of Esl1 -/-versus WT cartilage lysates. α-Tubulin is used as a loading control. The ratio of mature TGF-β2 to total TGF-β2 is shown at right. (B) ESL-1 inhibits the intracellular cleavage of proTGF-β1 in vitro. The scheme of transfections and chemical treatments of COS7 cells is shown at the top. Primary antibodies and molecular weights are denoted. Both proTGF-β1-V5 (50 kDa) and the mature TGF-β1-V5 (15 kDa) can be detected by V5 antibody. Note that the amount of 15-kDa TGF-β1 (*) was significantly reduced in the presence of ESL-1. Under nonreducing condition, the presence of ESL-1 remarkably increased proTGF-β1 dimer (100 kDa). LAP1 (37 kDa) was decreased in the presence of ESL-1. α-Tubulin, as an internal control, was similar in all samples. Expression of ESL-1 reduced the secretion of mature TGF-β1 ligand found in medium. Baf, bafilomycin; Chx, cycloheximide. (C) ESL-1 inhibits furin processing of proTGF-β1 by in vitro furin assay. Western blot analysis of the furin reaction samples with V5 antibody. Reaction time (Rxn time), plasmids for transfections, and identity of the bands are noted. Furin inhibitor II (hexa-d-arginine) was added in the last sample (180 min + FI) to confirm the specificity of the furin reaction. The ratios of cleaved to uncleaved TGF-β1 at all time points is shown. The proportion of mature TGF-β1 ligand is greatly increased after 30 minutes incubation in the absence of ESL-1.
and Golgi apparatus ( Figure 8D ). In contrast, when coexpressed with ESL-1, TGF-β1 was more concentrated in the Golgi apparatus (Figure 8, H-J) . Because of the limitation of overexpression studies, we further assayed for TGF-β distribution in the loss-offunction context using Esl1 -/-MEFs. We stained the MEFs isolated from Esl1 -/-and WT embryos with TGF-β1 antibody. Statistically, TGF-β1 was localized more abundantly in the Golgi apparatus of WT versus mutant MEFs (Esl1 -/-24% versus WT 69% using the same acquisition thresholds) (Figure 8, K-S) . Hence, as predicted, gain and loss of function of ESL-1 altered TGF-β subcellular localization in opposite directions.
Discussion
The net effect of TGF-β signaling determines the specification of cell differentiation, growth, and matrix synthesis. It is the product of complex regulatory mechanisms that control secretion, activa- . TGF-β1 is abundantly localized in Golgi apparatus (O), which is largely colocalized with Golgin97 (N and P). In Esl1 -/-MEFs, TGF-β1 is more evenly distributed in the cytoplasm (R). The merged image (S) of TGF-β1 (R) and Golgin97 (Q) indicates weaker colocalization of TGF-β with the Golgi apparatus. All tissue sections or cells described above were counterstained with DAPI (blue).
tion, receptor engagement, and intracellular signaling (23) (24) (25) . Tissues synthesize ample amounts of TGF-βs, but only a small fraction needs to be activated to trigger the downstream signaling events. Therefore, the bioavailability of TGF-βs must be tightly controlled by a variety of mechanisms at different levels. Current models for the regulation of TGF-β involve mechanisms for its secretion, extracellular activation in matrix, and antagonism of ligand-receptor interactions (3, 23) . However, besides the well-recognized latent TGF-β pool in the ECM, TGF-β is also abundantly localized in the cytoplasm, especially in the Golgi apparatus and ER prior to secretion (26, 27) . At the same time, the trans-Golgi network (TGN) is a localized concentration of abundant furin convertase activity in the cell. The colocalization of an intracellular TGF-β pool and TGN furin activity raise two important questions: (a) Is furin-dependent maturation of pro-TGF-β regulated?; and (b) Would such regulation be important in controlling TGF-β activity during development? Here, our data suggest that the answer to both questions is yes.
ESL-1, a Golgi protein, binds directly to proTGF-β in the Golgi apparatus and thus limits the processing of the maturation of TGF-β by furin convertase. Esl1 -/-cartilage showed increased mature TGF-β2 and p-Smad2. This was correlated with increased ECM deposition and decreased proliferation of chondrocytes. As a result, Esl1 -/-mice exhibit chondrodysplasia from embryonic stages. These data suggest not only that ESL-1 plays a role in regulating TGF-β bioavalibility, but also that this mechanism is important for skeletal development.
Furin has been recognized as a housekeeping protein that localizes in the TGN and plays an important role in proteolytically activating large numbers of proprotein substrates in the secretory pathway compartment. These include diverse signaling ligands, receptors, and pathogenic agents (28) . Because the furin-dependent processing affects multiple signaling pathways, simple regulation of furin expression and/or activation might not be sufficient to differentially control activation of diverse signaling pathways in response to environmental or physiological cues. Hence, pathwayspecific mechanisms for regulating furin-dependent processing might be one way to control the production and secretion of different morphogens and growth factors. Here, our findings suggest that ESL-1 serves such a novel function by preventing the maturation and secretion of TGF-β.
The expression pattern of ESL-1 overlaps that of TGF-βs in the skeleton and other organs. This supports the specific requirement of ESL-1 for normal TGF-β maturation. ESL-1 function is reminiscent of that of Emilin-1, which acts as a fine-tuning modulator of the TGF-β by regulating TGF-β proteolytic maturation, but in the ECM (20) . Although they act in different cellular compartments, the similarity of ESL-1 and Emilin's actions strongly suggest that the inhibition of the cleavage of proTGF-β is an important mode for regulating TGF-β bioavailability in general, and alteration of ESL-1 or Emilin function may lead to adverse homeostatic and/or developmental defects. We show that ESL-1's antagonism of TGF-β function is evolutionarily conserved, since overexpression of xEsl1 led to distinct TGF-β/Nodal-deficient phenotypes in the Xenopus embryos.
In mice, the loss of ESL-1 leads to increased TGF-β signaling in the growth plate and a chondrodysplasia phenotype. However, the consequences of TGF-β dysregulation in skeletal development and morphogenesis are complex, though their importance in vivo has been highlighted by different genetic disease phenotypes. ADAMTSL2 mutations in geleophysic dysplasia patients have recently been reported to cause elevated TGF-β secretion and activity, leading to disproportionate short stature and brachydactyly in humans (29) . In contrast, fibrillin1 mutations in Marfan syndrome exhibit increased TGF-β activity but result in tall stature. In earlier skeletal developmental stages, Esl1 is highly expressed in the perichondrium but at low levels in the cartilage. Similarly, fibrillin-1 and ADMTSL2 also exhibit strong expression in the perichondrium, where TGF-βs is abundantly synthesized, suggesting that the perichondrium is particularly important for production and regulation of TGF-β activity and regulation of the growth plate (9, 30, 31) . Previous studies have shown that the TGF-β1 inhibition of chondrocyte proliferation and differentiation in the long bones requires an intact perichondrium (32, 33) . PTHrP plays a central role in maintaining proliferating chondrocytes in an undifferentiating state by relaying TGF-β signaling to the cartilage in a perichondriumdependent manner (16, 34) . This is consistent with our observation that Esl1 -/-growth plates exhibited delayed terminal differentiation, with increased PTHrP and reduced IHH expression. However, the decreased proliferation in Esl1 -/-chondrocytes may rely on a PTHrP/IHH axis-independent mechanism. Esl1 expression is increased in PZ of growth plate in later skeletal development, suggesting that Esl1 and its TGF-β modulator function are regulated in a temporal-spatial fashion. The perichondrium and growth plate cartilage expresses other critical chondrogenesis signaling factors, including FGF18, Wnt, PTHrP, BMPs, etc. Hence, in those aforementioned TGF-β overactivation genetic models, the temporal-spatial differences in TGF-β activation can lead to diverse signaling interactions with other pathways. This most likely helps to determine the precise regulation of growth plate homeostasis and helps to explain why TGF-β overactivation in different genetic models can exhibit diverse outcomes in the skeletal system.
The functional complexity and context dependence of TGF-β signaling necessitate a similarly diverse and complex set of regulators that control TGF-β bioavailability in both a temporal and spatial fashion. Our results indicate that ESL-1 constitutes a mechanism at the cellular level for controlling proteolytic maturation and Golgi retention. Moreover, ESL-1 is broadly expressed in many other organs and tissues in addition to the skeletal system. Therefore, dysregulation of ESL-1 may be involved in other pathological conditions where dysregulation of TGF-β plays a central role. This includes cancer progression, immune dysregulation, osteoblast/ osteoclast coupling, and fibrosis/inflammations. Interestingly, ESL-1 cooperates with PSGL-1 and CD44 to regulate neutrophil rolling, which is critical for recruitment of neutrophils to inflamed tissues (35) . However, whether ESL-1 might specify TGF-β bioavailability during immune responses remains to be studied. Additionally, a posttranslationally modified ESL-1 variant with a unique carbohydrate epitope was specifically overexpressed on the surface of almost all epithelial cancers at precursor stages (21) . Whether the dramatically changed subcellular localization of ESL-1 causes a dysregulation of TGF-β that might contribute to the onset and/or progression of cancer is still unknown. In summary, as what we believe to be a novel intracellular inhibitor for TGF-β bioavailability, ESL-1 may serve as a therapeutic target for regulating TGF-β during different disease processes, such as arthritis and cancer, and the Esl1 -/-mouse will be a useful model to address these other questions. Statistics. We conduct statistical analyses by ANOVA with Student's t test. The error bars in the histograms show mean ± SD. A P value less than 0.05 was considered statistically significant.
